Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
05
2019
accepted:
22
07
2019
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
24
3
2020
Statut:
epublish
Résumé
The soluble urokinase plasminogen activator receptor (suPAR) is related to hepatic inflammation and fibrosis and has been suggested to participate in the development of liver cirrhosis. Therefore, the aim of the current study was to measure the concentration of suPAR in the hepatic vein of cirrhotic patients during a liver vein catheterization to identify a possible hepatic suPAR generation. Furthermore, we explored if suPAR levels were associated with the degree of cirrhosis and liver dysfunction. We included 105 cirrhotic patients and 19 liver-healthy controls. Blood was sampled from the hepatic vein and the femoral artery and suPAR was measured by enzyme-linked immunosorbent assay. We identified significantly higher median suPAR concentrations among the cirrhotic patients (7.2 ng/ml in the hepatic vein; 6.8 ng/ml in the femoral artery) compared to the controls (2.6 ng/ml, respectively, p-values <0.001). However, the median hepatic suPAR formation was 0.0 ng/ml in both groups. We observed significantly increasing suPAR levels according to higher Child classes (4.5 ng/ml, 6.9 ng/ml and 9.0 ng/ml, Child A, B, C respectively; p-value<0.001), and significantly higher median suPAR concentrations in patients with ascites versus patients without ascites (8.1 ng/ml versus 5.3 ng/ml, respectively, p-value<0.001). suPAR levels were significantly related to bilirubin (r = 0.48, p<0.001), the hepatic venous pressure gradient (r = 0.39, p<0.001), the cardiac index (r = 0.24, p = 0.02) and the plasma volume (r = 0.33, p = 0.001), whereas suPAR levels were significantly inversely related to albumin (r = -0.59, p<0.001), plasma coagulation factors (r-0.39, p<0.001), the mean arterial pressure (r = -0.28, p = 0.004), the systemic vascular resistance (r = 0.26, p = 0.007), the indocyanine green clearance (r = -0.51, p<0,001) and the galactose elimination capacity (r = -0.39, p<0.001). We identified elevated suPAR concentration in cirrhotic patients, which correlated significantly with the degree of cirrhosis and liver failure, but we were not able to demonstrate hepatic suPAR generation per se. This suggests that further investigations of the source of suPAR in cirrhotic patients need to be undertaken.
Sections du résumé
BACKGROUND
The soluble urokinase plasminogen activator receptor (suPAR) is related to hepatic inflammation and fibrosis and has been suggested to participate in the development of liver cirrhosis. Therefore, the aim of the current study was to measure the concentration of suPAR in the hepatic vein of cirrhotic patients during a liver vein catheterization to identify a possible hepatic suPAR generation. Furthermore, we explored if suPAR levels were associated with the degree of cirrhosis and liver dysfunction.
METHODS AND PATIENTS
We included 105 cirrhotic patients and 19 liver-healthy controls. Blood was sampled from the hepatic vein and the femoral artery and suPAR was measured by enzyme-linked immunosorbent assay.
RESULTS
We identified significantly higher median suPAR concentrations among the cirrhotic patients (7.2 ng/ml in the hepatic vein; 6.8 ng/ml in the femoral artery) compared to the controls (2.6 ng/ml, respectively, p-values <0.001). However, the median hepatic suPAR formation was 0.0 ng/ml in both groups. We observed significantly increasing suPAR levels according to higher Child classes (4.5 ng/ml, 6.9 ng/ml and 9.0 ng/ml, Child A, B, C respectively; p-value<0.001), and significantly higher median suPAR concentrations in patients with ascites versus patients without ascites (8.1 ng/ml versus 5.3 ng/ml, respectively, p-value<0.001). suPAR levels were significantly related to bilirubin (r = 0.48, p<0.001), the hepatic venous pressure gradient (r = 0.39, p<0.001), the cardiac index (r = 0.24, p = 0.02) and the plasma volume (r = 0.33, p = 0.001), whereas suPAR levels were significantly inversely related to albumin (r = -0.59, p<0.001), plasma coagulation factors (r-0.39, p<0.001), the mean arterial pressure (r = -0.28, p = 0.004), the systemic vascular resistance (r = 0.26, p = 0.007), the indocyanine green clearance (r = -0.51, p<0,001) and the galactose elimination capacity (r = -0.39, p<0.001).
CONCLUSION
We identified elevated suPAR concentration in cirrhotic patients, which correlated significantly with the degree of cirrhosis and liver failure, but we were not able to demonstrate hepatic suPAR generation per se. This suggests that further investigations of the source of suPAR in cirrhotic patients need to be undertaken.
Identifiants
pubmed: 31465463
doi: 10.1371/journal.pone.0220697
pii: PONE-D-19-12335
pmc: PMC6715219
doi:
Substances chimiques
PLAUR protein, human
0
Receptors, Urokinase Plasminogen Activator
0
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220697Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hepatology. 2004 Feb;39(2):280-2
pubmed: 14767976
Hepatology. 2004 Feb;39(2):286-90
pubmed: 14767978
BMC Gastroenterol. 2006 Nov 29;6:40
pubmed: 17134505
Clin Exp Immunol. 2008 Apr;152(1):163-73
pubmed: 18279442
Mol Cell Biochem. 2009 Jan;321(1-2):111-22
pubmed: 18830568
Exp Hematol. 2008 Dec;36(12):1616-24
pubmed: 18954937
Dis Markers. 2009;27(3):157-72
pubmed: 19893210
Blood. 2010 Sep 2;116(9):1593-603
pubmed: 20466854
J Intern Med. 2010 Sep;268(3):296-308
pubmed: 20561148
Eur J Clin Microbiol Infect Dis. 2011 Jun;30(6):761-6
pubmed: 21229279
Gut. 2011 Sep;60(9):1254-9
pubmed: 21504996
Nat Med. 2011 Jul 31;17(8):952-60
pubmed: 21804539
J Clin Gastroenterol. 2012 Apr;46(4):334-8
pubmed: 21934527
Liver Int. 2012 Mar;32(3):500-9
pubmed: 22098627
Scand J Gastroenterol. 2012 Sep;47(8-9):887-92
pubmed: 22809270
Crit Care. 2012 Jul 23;16(4):R130
pubmed: 22824423
J Intern Med. 2013 Jul;274(1):86-100
pubmed: 23432143
Liver Int. 2013 Oct;33(9):1309-15
pubmed: 23763259
Liver Int. 2014 Jul;34(6):e19-30
pubmed: 24313898
Eur J Clin Invest. 2014 May;44(5):441-52
pubmed: 24476551
Transl Res. 2015 Jun;165(6):658-66
pubmed: 25445207
Dig Dis Sci. 2015 Nov;60(11):3209-25
pubmed: 26112989
Wien Klin Wochenschr. 2016 Jan;128(1-2):28-33
pubmed: 26546355
Nat Med. 2017 Jan;23(1):100-106
pubmed: 27941791
Crit Rev Clin Lab Sci. 2017 Mar;54(2):117-133
pubmed: 28084848